Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Iovance Biotherapeutics Inc banner

Iovance Biotherapeutics Inc
F:2LB

Watchlist Manager
Iovance Biotherapeutics Inc Logo
Iovance Biotherapeutics Inc
F:2LB
Watchlist
Price: 3.705 EUR -5.61% Market Closed
Market Cap: €1B
Write Note Create Alert Ask AI

Wall St Price Targets

2LB Price Targets Summary
Iovance Biotherapeutics Inc

Wall Street analysts forecast 2LB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 2LB is 3.871 EUR with a low forecast of 1.865 EUR and a high forecast of 6.785 EUR.

2LB Lowest Forecast
Wall Street Target
€1.865
-50% Downside
2LB Average Forecast
Wall Street Target
€3.871
4% Upside
2LB Highest Forecast
Wall Street Target
€6.785
83% Upside
Lowest Forecast
Price Target
1.865 EUR
50% Downside
Average Forecast
Price Target
3.871 EUR
4% Upside
Highest Forecast
Price Target
6.785 EUR
83% Upside
Iovance Biotherapeutics Inc Competitors:
Price Targets
MRVL
Marvell Technology Group Ltd
17% Upside
V
VERK
Verkkokauppa.com Oyj
15% Upside
QNST
Quinstreet Inc
25% Upside
F
3363
FOCI Fiber Optic Communications Inc
25% Upside
MRVL
Marvell Technology Group Ltd
17% Upside
V
VERK
Verkkokauppa.com Oyj
15% Upside
QNST
Quinstreet Inc
25% Upside
F
3363
FOCI Fiber Optic Communications Inc
25% Upside

Revenue
Forecast

N/A
Past Growth
29% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
N/A
Past Growth
29% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

The compound annual growth rate for Revenue over the next 8 years is 29%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
43% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat
N/A
Past Growth
43% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat

The compound annual growth rate for Gross Profit over the next 8 years is 43%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

What are analyst estimates?

Continue 2LB Research

Summary
2LB intrinsic value, competitors valuation, and company profile.
DCF Valuation
2LB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
2LB stock valuation using valuation multiples.
Wall St Estimates
2LB price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
2LB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Iovance Biotherapeutics Inc listings:
NASDAQ • USD
IOVA
 LSE • USD
0JDK
 SWB • EUR
2LB
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 2LB's stock price target?
Price Target
3.871 EUR

According to Wall Street analysts, the average 1-year price target for 2LB is 3.871 EUR with a low forecast of 1.865 EUR and a high forecast of 6.785 EUR.

What is the Revenue forecast for Iovance Biotherapeutics Inc?
Projected CAGR
29%

The compound annual growth rate for Revenue over the next 8 years is 29%.

What is the Gross Profit forecast for Iovance Biotherapeutics Inc?
Projected CAGR
43%

The compound annual growth rate for Gross Profit over the next 8 years is 43%.

Back to Top
ALPHA SPREAD
Follow us
Join 351,300+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett